This announcement is made by Peijia Medical Limited (the “Company”, together with its subsidiaries, the “Group”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.
The board (the “Board”) of directors (the “Directors”) of the Company is pleased to announce that on June 29, 2023, the Group received the approval from the National Medical Products Administration of the PRC (國家藥品監(jiān)督管理局) (the “NMPA”) for the registration application of DCwireTM Micro Guidewire, making it the Group’s fifteenth NMPA approved neurointerventional product.
DCwireTM Micro Guidewire is a product developed by Achieva Medical Limited (“Achieva”), a wholly-owned subsidiary of the Company, and is designed based on the idea of “microstructure”. The term “microstructure” refers to the design of a multi-layered micro-structured device made of multiple materials through precision manufacturing. Due to the thin and tortuous nature of intracranial vessels, devices are required to be controlled and operated through tight spaces, and therefore, there is a heightened demand for precision with respect to the design and manufacturing of such devices. DCwireTM Micro Guidewire has realized the manufacturing precision as well as the unique material properties of “microstructure”, which allows the device to be precisely controlled and easy to super select vessels, enabling physicians build vascular access quickly and more easily during procedures.
DCwireTM Micro Guidewire is a new-generation neurointerventional micro guidewire developed by Achieva. NMPA approval for the registration application of DCwireTM Micro Guidewire is another significant step for the Company to enhance a well-rounded product portfolio for stroke treatment. We will continue to develop innovative products to help more patients maintain health and well-being.
